Remdesivir for the Treatment of Covid-19 - Preliminary Report.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 5 syntheses or guidelines pooled it.

1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
   Pooled it
2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
   Pooled it
3. Efficacy of early use of remdesivir: a systematic review of subgroup analysis.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
   Pooled it
4. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis.Infection · 2022
   Pooled it
5. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2021
   Pooled it
6. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.JAMA network open · 2021
   Trial
7. A Concise Review of Major Challenges in the Vaccination, Diagnosis and Treatment of Novel Coronavirus Disease 2019.Archives of Razi Institute · 2024
   Review
8. A narrative review on adverse drug reactions of COVID-19 treatments on the kidney.Open medicine (Warsaw, Poland) · 2024
   Review
9. Dynamic heterogeneity in COVID-19: Insights from a mathematical model.PloS one · 2024
   Article
10. Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches.Drug design, development and therapy · 2024
    Review
11. Mortality in ICU Patients with COVID-19-Associated Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2023
    Review
12. Clinical outcomes of remdesivir-treated COVID-19 patients in South Korea.Osong public health and research perspectives · 2022
    Article
13. The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.Medicina (Kaunas, Lithuania) · 2022
    Review
14. Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.European journal of medicinal chemistry · 2021
    Article
15. Cyclodextrins in the antiviral therapy.Journal of drug delivery science and technology · 2021
    Review
16. Rapid recovery achieved by intensive therapy after preterm cesarean section for worsening COVID-19-induced acute respiratory failure: A case report and literature review.Case reports in women's health · 2021
    Article
17. Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa.Open forum infectious diseases · 2021
    Article
18. SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus.Membranes · 2021
    Review

Corrections and comments

• Commented on by
  Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.2020
• Comment on
  Remdesivir for the Treatment of Covid-19 - Final Report.2020

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as